REFERENCES
1. Yesil A, Yilmaz Y. Review article: coffee consumption, the metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013;38:1038-44.
2. Huxley R, Lee CM, Barzi F, et al. Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis. Arch Intern Med 2009;169:2053-63.
3. Lopez-Garcia E, Rodriguez-Artalejo F, Rexrode KM, Logroscino G, Hu FB, van Dam RM. Coffee consumption and risk of stroke in women. Circulation 2009;119:1116-23.
4. Larsson SC, Männistö S, Virtanen MJ, Kontto J, Albanes D, Virtamo J. Coffee and tea consumption and risk of stroke subtypes in male smokers. Stroke 2008;39:1681-7.
5. Larsson SC, Virtamo J, Wolk A. Coffee consumption and risk of stroke in women. Stroke 2011;42:908-12.
6. Ruhl CE, Everhart JE. Association of coffee consumption with gallbladder disease. Am J Epidemiol 2000;152:1034-8.
7. Ascherio A, Zhang SM, Hernán MA, et al. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 2001;50:56-63.
8. Wu JN, Ho SC, Zhou C, et al. Coffee consumption and risk of coronary heart diseases: a meta-analysis of 21 prospective cohort studies. Int J Cardiol 2009;137:216-25.
9. Freedman ND, Park Y, Abnet CC, Hollenbeck AR, Sinha R. Association of coffee drinking with total and cause-specific mortality. N Engl J Med 2012;366:1891-904.
10. Klatsky AL, Morton C, Udaltsova N, Friedman GD. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med 2006;166:1190-5.
11. Nakanishi N, Nakamura K, Nakajima K, Suzuki K, Tatara K. Coffee consumption and decreased serum γ-glutamyltransferase: a study of middle-aged Japanese men. Eur J Epidemiol 2000;16:419-23.
12. Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005;128:24-32.
13. Modi AA, Feld JJ, Park Y, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010;51:201-9.
14. Ruhl CE, Everhart JE. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 2005;129:1928-36.
15. Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE. HALT-C TRIAL GROUP. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology 2011;140:1961-9.
16. Corrao G, Zambon A, Bagnardi V, D’amicis A, Klatsky A. Coffee, Caffeine, and the Risk of Liver Cirrhosis. Ann Epidemiol 2001;11:458-65.
17. Gallus S, Tavani A, Negri E, La Vecchia C. Does Coffee Protect Against Liver Cirrhosis? Ann Epidemiol 2002;12:202-5.
18. Birerdinc A, Stepanova M, Pawloski L, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012;35:76-82.
19. Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012;55:429-36.
20. Klatsky AL, Armstrong MA. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol 1992;136:1248-57.
21. Tverdal A, Skurtveit S. Coffee Intake and Mortality from Liver Cirrhosis. Annals of Epidemiology 2003;13:419-23.
22. Gallus S, Bertuzzi M, Tavani A, et al. Does coffee protect against hepatocellular carcinoma? Br J Cancer 2002;87:956-9.
23. Gelatti U, Covolo L, Franceschini M, et al. Brescia HCC Study Group. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol 2005;42:528-34.
24. Shimazu T, Tsubono Y, Kuriyama S, et al. Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan. Int J Cancer 2005;116:150-4.
25. Inoue M, Yoshimi I, Sobue T, Tsugane S. JPHC Study Group. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005;97:293-300.
26. Hu G, Tuomilehto J, Pukkala E, et al. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology 2008;48:129-36.
27. Petrick JL, Freedman ND, Graubard BI, et al. Coffee consumption and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma by sex: the liver cancer pooling project. Cancer Epidemiol Biomarkers Prev 2015;24:1398-406.
28. Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 2007;132:1740-5.
29. Bravi F, Bosetti C, Tavani A, et al. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology 2007;46:430-5.
30. Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol 2013;11:1413-21.e1.
31. Bravi F, Tavani A, Bosetti C, Boffetta P, La Vecchia C. Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies. Eur J Cancer Prev 2017;26:368-77.
32. Hosaka S, Kawa S, Aoki Y, et al. Hepatocarcinogenesis inhibition by caffeine in ACI rats treated with 2-acetylaminofluorene. Food Chem Toxicol 2001;39:557-61.
33. Huber WW, Prustomersky S, Delbanco E, et al. Enhancement of the chemoprotective enzymes glucuronosyl transferase and glutathione transferase in specific organs of the rat by the coffee components kahweol and cafestol. Arch Toxicol 2002;76:209-17.
34. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
36. Ambade A, Mandrekar P. Oxidative stress and inflammation: essential partners in alcoholic liver disease. Int J Hepatol 2012;2012:853175.
37. Butt MS, Sultan MT. Coffee and its consumption: benefits and risks. Crit Rev Food Sci Nutr 2011;51:363-73.
39. Ratnayake W, Hollywood R, O’grady E, Stavric B. Lipid content and composition of coffee brews prepared by different methods. Food Chem Toxicol 1993;31:263-9.
40. Dranoff JA. Coffee Consumption and Prevention of Cirrhosis: In Support of the Caffeine Hypothesis. Gene Expr 2018;18:1-3.
42. Yashin A, Yashin Y, Wang JY, Nemzer B. Antioxidant and antiradical activity of coffee. Antioxidants ;2:230-45.
43. Anese M, Nicoli MC. Antioxidant properties of ready-to-drink coffee brews. J Agric Food Chem 2003;51:942-6.
44. Anty R, Marjoux S, Iannelli A, et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol 2012;57:1090-6.
45. Urgert R, Schulz AG, Katan MB. Effects of cafestol and kahweol from coffee grounds on serum lipids and serum liver enzymes in humans. Am J Clin Nutr 1995;61:149-54.
46. Saab S, Mallam D, Cox GA 2nd, Tong MJ. Impact of coffee on liver diseases: a systematic review. Liver Int 2014;34:495-504.
47. Duarte GS, Farah A. Effect of simultaneous consumption of milk and coffee on chlorogenic acids’ bioavailability in humans. J Agric Food Chem 2011;59:7925-31.
48. Tran KT, Coleman HG, McMenamin ÚC, Cardwell CR. Coffee consumption by type and risk of digestive cancer: a large prospective cohort study. Br J Cancer 2019;120:1059-66.
49. La Vecchia C, Ferraroni M, Negri E, D’Avanzo B, Decarli A, et al. Coffee consumption and digestive tract cancers. Cancer Res 1989;49:1049-51.
50. Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000;85:498-502.
51. Montella M, Polesel J, La Vecchia C, et al. Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. Int J Cancer 2007;120:1555-9.
52. Tanaka K, Hara M, Sakamoto T, et al. Inverse association between coffee drinking and the risk of hepatocellular carcinoma: a case-control study in Japan. Cancer Sci 2007;98:214-8.
53. Johnson S, Koh WP, Wang R, Govindarajan S, Yu MC, Yuan JM. Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Cancer Causes Control 2011;22:503-10.
54. Setiawan VW, Wilkens LR, Lu SC, Hernandez BY, Le Marchand L, Henderson BE. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 2015;148:118-25; quiz e15.
55. Lai GY, Weinstein SJ, Albanes D, et al. The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. Br J Cancer 2013;109:1344-51.
56. Bamia C, Lagiou P, Jenab M, et al. Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. Int J Cancer 2015;136:1899-908.
57. Aleksandrova K, Bamia C, Drogan D, et al. The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2015;102:1498-508.
58. Kurozawa Y, Ogimoto I, Shibata A, et al. JACC Study Group. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer 2005;93:607-10.
59. Wakai K, Kurozawa Y, Shibata A, et al. JACC Study Group. Liver cancer risk, coffee, and hepatitis C virus infection: a nested case-control study in Japan. Br J Cancer 2007;97:426-8.
60. Ohfuji S, Fukushima W, Tanaka T, et al. Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: A case-control study. Hepatol Res 2006;36:201-8.
61. Jang ES, Jeong SH, Lee SH, et al. The effect of coffee consumption on the development of hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int 2013;33:1092-9.
62. Leung WW, Ho SC, Chan HL, Wong V, Yeo W, Mok TS. Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. J Epidemiol Community Health 2011;65:556-8.
63. Bravi F, Bosetti C, Tavani A, La Vecchia C. Coffee drinking and hepatocellular carcinoma: an update. Hepatology 2009;50:1317-8.
64. Sang LX, Chang B, Li XH, Jiang M. Consumption of coffee associated with reduced risk of liver cancer: a meta-analysis. BMC Gastroenterol 2013;13:34.
65. Bai K, Cai Q, Jiang Y, Lv L. Coffee consumption and risk of hepatocellular carcinoma: a meta-analysis of eleven epidemiological studies. Onco Targets Ther 2016;9:4369-75.
66. Yu C, Cao Q, Chen P, et al. An updated dose-response meta-analysis of coffee consumption and liver cancer risk. Sci Rep 2016;6:37488.
67. Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis. BMJ Open 2017;7:e013739.
68. Bhurwal A, Rattan P, Yoshitake S, et al. Inverse association of coffee with liver cancer development: an updated systematic review and meta-analysis. J Gastrointestin Liver Dis 2020;29:421-8.
69. Inoue M, Kurahashi N, Iwasaki M, et al. Japan Public Health Center-Based Prospective Study Group. Effect of coffee and green tea consumption on the risk of liver cancer: cohort analysis by hepatitis virus infection status. Cancer Epidemiol Biomarkers Prev 2009;18:1746-53.
70. Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008;48:993-9.
71. Desmond PV, Patwardhan RV, Johnson RF, Schenker S. Impaired elimination of caffeine in cirrhosis. Dig Dis Sci 1980;25:193-7.
72. Vecchia C. Cancer and liver cancer prevention: is it a fact or just a potential? Hepatology 2008;48:7-9.
73. Holstege A, Staiger M, Haag K, Gerok W. Correlation of caffeine elimination and Child’s classification in liver cirrhosis. Klin Wochenschr 1989;67:6-15.
74. Jost G, Wahlländer A, von Mandach U, Preisig R. Overnight salivary caffeine clearance: a liver function test suitable for routine use. Hepatology 1987;7:338-44.
75. McDonagh JE, Nathan VV, Bonavia IC, Moyle GR, Tanner AR. Caffeine clearance by enzyme multiplied immunoassay technique: a simple, inexpensive, and useful indicator of liver function. Gut 1991;32:681-4.
76. Lewis FW, Rector WG. Caffeine clearance in cirrhosis. The value of simplified determinations of liver metabolic capacity. J Hepatol 1992;14:157-62.
77. Tarantino G, Conca P, Capone D, Gentile A, Polichetti G, Basile V. Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients. Eur J Clin Pharmacol 2006;62:605-12.
78. Farinati F, Dalri’ L, Rossaro L, et al. Serum and salivary caffeine clearance in cirrhosis. Any role in selection for surgery and timing for transplantation? J Hepatol 1993;18:135-6.
79. Zhao LG, Li ZY, Feng GS, et al. Coffee drinking and cancer risk: an umbrella review of meta-analyses of observational studies. BMC Cancer 2020;20:101.
80. Shim SG, Jun DW, Kim EK, et al. Caffeine attenuates liver fibrosis via defective adhesion of hepatic stellate cells in cirrhotic model. J Gastroenterol Hepatol 2013;28:1877-84.
81. Sinha RA, Farah BL, Singh BK, et al. Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice. Hepatology 2014;59:1366-80.
82. Lv X, Chen Z, Li J, et al. Caffeine protects against alcoholic liver injury by attenuating inflammatory response and oxidative stress. Inflamm Res 2010;59:635-45.
83. Wang Q, Dai X, Yang W, et al. Caffeine protects against alcohol-induced liver fibrosis by dampening the cAMP/PKA/CREB pathway in rat hepatic stellate cells. Int Immunopharmacol 2015;25:340-52.
84. Arauz J, Zarco N, Segovia J, Shibayama M, Tsutsumi V, Muriel P. Caffeine prevents experimental liver fibrosis by blocking the expression of TGF-β. Eur J Gastroenterol Hepatol 2014;26:164-73.
85. Okano J. Preventive effect of caffeine and curcumin on hepato-carcinogenesis in diethylnitrosamine-induced rats. Int J Oncol 2012; doi: 10.3892/ijo.2012.1343.
86. Tverdal A, Hjellvik V, Selmer R. Coffee intake and oral-oesophageal cancer: follow-up of 389,624 Norwegian men and women 40-45 years. Br J Cancer 2011;105:157-61.
87. Edling CE, Selvaggi F, Ghonaim R, Maffucci T, Falasca M. Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway. Cancer Biol Ther 2014;15:524-32.
88. Mori H, Tanaka T, Shima H, Kuniyasu T, Takahashi M. Inhibitory effect of chlorogenic acid on methylazoxymethanol acetate-induced carcinogenesis in large intestine and liver of hamsters. Cancer Letters 1986;30:49-54.
89. Yan Y, Liu N, Hou N, Dong L, Li J. Chlorogenic acid inhibits hepatocellular carcinoma in vitro and in vivo. J Nutr Biochem 2017;46:68-73.
90. Sato Y, Itagaki S, Kurokawa T, et al. In vitro and in vivo antioxidant properties of chlorogenic acid and caffeic acid. Int J Pharm 2011;403:136-8.
91. Yun N, Kang JW, Lee SM. Protective effects of chlorogenic acid against ischemia/reperfusion injury in rat liver: molecular evidence of its antioxidant and anti-inflammatory properties. J Nutr Biochem 2012;23:1249-55.
92. Torres DM, Harrison SA. Is it time to write a prescription for coffee? Gastroenterology 2013;144:670-2.
93. Schilter B, Perrin I, Cavin C, Huggett AC. Placental glutathione S-transferase (GST-P) induction as a potential mechanism for the anti-carcinogenic effect of the coffee-specific components cafestol and kahweol. Carcinogenesis 1996;17:2377-84.
94. Cavin C, Holzhäuser D, Constable A, Huggett AC, Schilter B. The coffee-specific diterpenes cafestol and kahweol protect against aflatoxin B1-induced genotoxicity through a dual mechanism. Carcinogenesis 1998;19:1369-75.
95. Huber WW, Rossmanith W, Grusch M, et al. Effects of coffee and its chemopreventive components kahweol and cafestol on cytochrome P450 and sulfotransferase in rat liver. Food Chem Toxicol 2008;46:1230-8.
96. Sparnins V, Venegas P, Wattenberg L. Glutathione S-transferase activity: enhancement by compounds inhibiting chemical carcinogenesis and by dietary constituents. J Natl Cancer Inst 1982;68:493-6.
97. Higgins LG, Cavin C, Itoh K, Yamamoto M, Hayes JD. Induction of cancer chemopreventive enzymes by coffee is mediated by transcription factor Nrf2. Evidence that the coffee-specific diterpenes cafestol and kahweol confer protection against acrolein. Toxicol Appl Pharmacol 2008;226:328-37.
98. Cavin C, Holzhaeuser D, Scharf G, Constable A, Huber W, Schilter B. Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. Food Chem Toxicol 2002;40:1155-63.
99. Lee KJ, Choi JH, Jeong HG. Hepatoprotective and antioxidant effects of the coffee diterpenes kahweol and cafestol on carbon tetrachloride-induced liver damage in mice. Food Chem Toxicol 2007;45:2118-25.
100. Vitaglione P, Morisco F, Mazzone G, et al. Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. Hepatology 2010;52:1652-61.
101. Chen S, Teoh NC, Chitturi S, Farrell GC. Coffee and non-alcoholic fatty liver disease: brewing evidence for hepatoprotection? J Gastroenterol Hepatol 2014;29:435-41.
102. Hasegawa R, Ogiso T, Imaida K, Shirai T, Ito N. Analysis of the potential carcinogenicity of coffee and its related compounds in a medium-term liver bioassay of rats. Food Chem Toxicol 1995;33:15-20.
103. Miura Y, Ono K, Okauchi R, Yagasaki K. Inhibitory effect of coffee on hepatoma proliferation and invasion in culture and on tumor growth, metastasis and abnormal lipoprotein profiles in hepatoma-bearing rats. J Nutr Sci Vitaminol (Tokyo) 2004;50:38-44.
104. Silva-Oliveira EM, Fernandes PA, Moraes-Santos T. Effect of coffee on chemical hepatocarcinogenesis in rats. Nutr Cancer 2010;62:336-42.
105. Furtado KS, Polletini J, Dias MC, Rodrigues MA, Barbisan LF. Prevention of rat liver fibrosis and carcinogenesis by coffee and caffeine. Food Chem Toxicol 2014;64:20-6.
106. Ferk F, Huber WW, Grasl-Kraupp B, et al. Protective effects of coffee against induction of DNA damage and pre-neoplastic foci by aflatoxin B1. Mol Nutr Food Res 2014;58:229-38.
107. Katayama M, Donai K, Sakakibara H, et al. Coffee consumption delays the hepatitis and suppresses the inflammation related gene expression in the Long-Evans Cinnamon rat. Clin Nutr 2014;33:302-10.
108. Svilaas A, Sakhi AK, Andersen LF, et al. Intakes of antioxidants in coffee, wine, and vegetables are correlated with plasma carotenoids in humans. J Nutr 2004;134:562-7.
109. Balstad TR, Carlsen H, Myhrstad MC, et al. Coffee, broccoli and spices are strong inducers of electrophile response element-dependent transcription in vitro and in vivo - studies in electrophile response element transgenic mice. Mol Nutr Food Res 2011;55:185-97.
110. Bøhn SK, Blomhoff R, Paur I. Coffee and cancer risk, epidemiological evidence, and molecular mechanisms. Mol Nutr Food Res 2014;58:915-30.
111. Farinati F, Cardin R, Degan P, et al. Oxidative DNA damage in circulating leukocytes occurs as an early event in chronic HCV infection. Free Radic Biol Med 1999;27:1284-91.
112. Farinati F, Cardin R, Bortolami M, et al. Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. J Viral Hepat 2007;14:821-9.
113. Piciocchi M, Cardin R, Cillo U, et al. Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus-related liver carcinogenesis. Transl Res 2016;168:122-33.
114. Poli G. Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 2000;21:49-98.
115. Shaposhnikov S, Hatzhol T, El Yamani N, et al. Coffee and oxidative stress: a human intervention study. Eur J Nutr 2018;57:533-44.
116. Cardin R, Piciocchi M, Martines D, Scribano L, Petracco M, Farinati F. Effects of coffee consumption in chronic hepatitis C: a randomized controlled trial. Dig Liver Dis 2013;45:499-504.
117. Pal S, Polyak SJ, Bano N, et al. Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1. J Gastroenterol Hepatol 2010;25:627-34.
118. Farinati F, Cardin R, De Maria N, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995;22:449-56.
119. Bortolami M, Kotsafti A, Cardin R, Farinati F. Fas/FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease. J Viral Hepat 2008;15:515-22.
120. Farinati F, Cardin R, Bortolami M, Guido M, Rugge M. Oxidative damage, pro-inflammatory cytokines, TGF-alpha and c-myc in chronic HCV-related hepatitis and cirrhosis. World J Gastroenterol 2006;12:2065-9.
121. Chuma M, Hige S, Nakanishi M, et al. 8-Hydroxy-2’-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2008;23:1431-6.
122. Oikawa S, Kawanishi S. Site-specific DNA damage at GGG sequence by oxidative stress may accelerate telomere shortening. FEBS Letters 1999;453:365-8.
124. Farinati F, Cardin R, Fiorentino M, et al. Imbalance between cytoproliferation and apoptosis in hepatitis C virus related chronic liver disease. J Viral Hepat 2001;8:34-40.
125. Farinati F, Cardin R, Bortolami M, Rugge M. Up and down regulation of apoptosis in hepatitis C virus-related liver damage. J Hepatol 2004;41:883-5; author reply 885.
126. Lopez-Garcia E, van Dam RM, Qi L, Hu FB. Coffee consumption and markers of inflammation and endothelial dysfunction in healthy and diabetic women. Am J Clin Nutr 2006;84:888-93.
127. Shin JW, Wang JH, Kang JK, Son CG. Experimental evidence for the protective effects of coffee against liver fibrosis in SD rats. J Sci Food Agric 2010;90:450-5.
129. Romualdo GR, Prata GB, da Silva TC, et al. The combination of coffee compounds attenuates early fibrosis-associated hepatocarcinogenesis in mice: involvement of miRNA profile modulation. J Nutr Biochem 2020;85:108479.
130. Catalano D, Martines GF, Tonzuso A, Pirri C, Trovato FM, Trovato GM. Protective role of coffee in non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2010;55:3200-6.
131. Gutiérrez-Grobe Y, Chávez-Tapia N, Sánchez-Valle V, et al. High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. Ann Hepatol 2012;11:350-5.
132. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013;10:656-65.
